BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 38256273)

  • 21. Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis.
    Petta S; Adinolfi LE; Fracanzani AL; Rini F; Caldarella R; Calvaruso V; Cammà C; Ciaccio M; Di Marco V; Grimaudo S; Licata A; Marrone A; Nevola R; Pipitone RM; Pinto A; Rinaldi L; Torres D; Tuttolomondo A; Valenti L; Fargion S; Craxì A
    J Hepatol; 2018 Jul; 69(1):18-24. PubMed ID: 29505844
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High rate of sustained virological response with direct-acting antivirals in haemophiliacs with HCV infection: A multicenter study.
    Mancuso ME; Linari S; Santagostino E; Bartolozzi D; D'Ambrosio R; Borghi M; Lampertico P; Peyvandi F; Castaman G; Aghemo A
    Liver Int; 2020 May; 40(5):1062-1068. PubMed ID: 31876354
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HCV cirrhotic patients treated with direct-acting antivirals: Detection of tubular dysfunction and resolution after viral clearance.
    Biliotti E; Palazzo D; Tinti F; D'Alessandro MD; Esvan R; Labriola R; Cappoli A; Umbro I; Volpicelli L; Bachetoni A; Villa E; Mitterhofer AP; Rucci P; Taliani G
    Liver Int; 2021 Jan; 41(1):158-167. PubMed ID: 32979012
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chronic genotype 1 hepatitis C along with cirrhosis drives a persistent imprint in virus-specific CD8
    Perpiñán E; Pérez-Del-Pulgar S; Londoño MC; Mariño Z; Lens S; Leonel T; Bartres C; García-López M; Rodriguez-Tajes S; Forns X; Koutsoudakis G
    J Viral Hepat; 2020 Dec; 27(12):1408-1418. PubMed ID: 32812325
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical impact of serum α-fetoprotein and its relation on changes in liver fibrosis in hepatitis C virus patients receiving direct-acting antivirals.
    Fouad R; Elsharkawy A; Abdel Alem S; El Kassas M; Alboraie M; Sweedy A; Afify S; Abdellatif Z; Khairy M; Esmat G
    Eur J Gastroenterol Hepatol; 2019 Sep; 31(9):1129-1134. PubMed ID: 30896550
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hepatitis C Virus Clearance in Older Adults.
    Ippolito AM; Iacobellis A; Milella M; Conti F; Messina V; Valvano MR; Niro GA; Morisco F; Barone M; Termite AP; Brancaccio G; Andriulli A
    J Am Geriatr Soc; 2018 Jan; 66(1):85-91. PubMed ID: 29135030
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity.
    Krassenburg LAP; Maan R; Ramji A; Manns MP; Cornberg M; Wedemeyer H; de Knegt RJ; Hansen BE; Janssen HLA; de Man RA; Feld JJ; van der Meer AJ
    J Hepatol; 2021 May; 74(5):1053-1063. PubMed ID: 33242501
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antiviral Therapy in Patients with Hepatitis C Virus-Induced Cirrhosis.
    Bailly F; Pradat P; Virlogeux V; Zoulim F
    Dig Dis; 2015; 33(4):613-23. PubMed ID: 26159282
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HCV eradication with all-oral therapy in cirrhotic HIV-coinfected patients: an observational study of early changes in liver function and fibrosis tests.
    Domínguez Domínguez L; Matarranz M; Lagarde M; Bisbal O; Hernando A; Lumbreras C; Rubio R; Pulido F
    Rev Esp Enferm Dig; 2019 Aug; 111(8):626-632. PubMed ID: 31240941
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hepatitis C Virus Eradication with New Interferon-Free Treatment Improves Metabolic Profile in Hepatitis C Virus-Related Liver Transplant Recipients.
    Beig J; Orr D; Harrison B; Gane E
    Liver Transpl; 2018 Aug; 24(8):1031-1039. PubMed ID: 29577581
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Platelet Count Improvement after Chronic Hepatitis C Treatment among Cirrhotic Patients Who Achieved Sustained Virological Response: Realworld Results from 2186 Patients in Egypt.
    Badawi R; Soliman S; Aboali L; Elkadeem M; Elfert A; Elguindy AMA; Ullah MS; Abd-Elsalam S
    Endocr Metab Immune Disord Drug Targets; 2021; 21(7):1300-1305. PubMed ID: 32940191
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reverse inflammaging: Long-term effects of HCV cure on biological age.
    Oltmanns C; Liu Z; Mischke J; Tauwaldt J; Mekonnen YA; Urbanek-Quaing M; Debarry J; Maasoumy B; Wedemeyer H; Kraft ARM; Xu CJ; Cornberg M
    J Hepatol; 2023 Jan; 78(1):90-98. PubMed ID: 36152762
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum Ceramide Species Are Associated with Liver Cirrhosis and Viral Genotype in Patients with Hepatitis C Infection.
    Höring M; Peschel G; Grimm J; Krautbauer S; Müller M; Weigand K; Liebisch G; Buechler C
    Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077197
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Elastography is unable to exclude cirrhosis after sustained virological response in HCV-infected patients with advanced chronic liver disease.
    Broquetas T; Herruzo-Pino P; Mariño Z; Naranjo D; Vergara M; Morillas RM; Forns X; Carrión JA
    Liver Int; 2021 Nov; 41(11):2733-2746. PubMed ID: 34525253
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Microbiota and hepatitis C virus in the era of direct-acting antiviral agents.
    Pinchera B; Moriello NS; Buonomo AR; Zappulo E; Viceconte G; Villari R; Gentile I
    Microb Pathog; 2023 Feb; 175():105968. PubMed ID: 36626945
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of serum sphingolipids as potential biomarkers of non-response to direct acting antiviral therapy in chronic hepatitis C virus infection.
    Röhrig AM; Jakobi K; Dietz J; Thomas D; Herrmann E; Welsch C; Sarrazin C; Pfeilschifter J; Zeuzem S; Grammatikos G
    J Viral Hepat; 2023 Feb; 30(2):138-147. PubMed ID: 36463431
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevalence and Outcome of Serum Autoantibodies in Chronic Hepatitis C Patients Undergoing Direct-Acting Antiviral Treatment.
    Romano C; Tortorella O; Dalla Mora L; Di Stasio D; Sellitto A; Adinolfi LE; Marrone A
    Front Immunol; 2022; 13():882064. PubMed ID: 35479086
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery and Development of Antiviral Therapies for Chronic Hepatitis C Virus Infection.
    Martinez MA; Franco S
    Adv Exp Med Biol; 2021; 1322():139-157. PubMed ID: 34258740
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enhanced immune responses, PI3K/AKT and JAK/STAT signaling pathways following hepatitis C virus eradication by direct-acting antiviral therapy among Egyptian patients: a case control study.
    Ramadan HK; Badr G; Ramadan NK; Sayed A
    Pathog Dis; 2021 Mar; 79(3):. PubMed ID: 33524139
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Factors associated with treatment failure of direct-acting antivirals for chronic hepatitis C: A real-world nationwide hepatitis C virus registry programme in Taiwan.
    Chen CY; Huang CF; Cheng PN; Tseng KC; Lo CC; Kuo HT; Huang YH; Tai CM; Peng CY; Bair MJ; Chen CH; Yeh ML; Lin CL; Lin CY; Lee PL; Chong LW; Hung CH; Huang JF; Yang CC; Hu JT; Lin CW; Chen CT; Wang CC; Su WW; Hsieh TY; Lin CL; Tsai WL; Lee TH; Chen GY; Wang SJ; Chang CC; Mo LR; Yang SS; Wu WC; Huang CS; Hsiung CK; Kao CN; Tsai PC; Liu CH; Lee MH; Liu CJ; Dai CY; Kao JH; Chuang WL; Lin HC; Yu ML
    Liver Int; 2021 Jun; 41(6):1265-1277. PubMed ID: 33655714
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.